GlassScriptPhysician profile
Richard Leshner
NPI 1114940210
$3,343.28
in general payments reported to CMS, 2019-2025
37 companies · $290 in 2025
The $290 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $865 · 2020: $588 · 2021: $513 · 2022: $354 · 2023: $393 · 2024: $340 · 2025: $290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,002 · Education: $21.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,001.86 |
| Education | $21.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $426.53 | 2019-2021 | |
| Boston Scientific Corporation | $387.67 | 2019-2025 | Watchman Flx, Watchman Access System, Lux-Dx Insertable Cardiac Monitor |
| Amgen INC. | $328.44 | 2019-2025 | Otezla, Repatha, Repatha |
| Amarin Pharma, INC. | $238.88 | 2019-2021 | |
| Pfizer INC. | $207.89 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $201.47 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $183.16 | 2019-2025 | Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $151.49 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $147.71 | 2021-2023 | Verquvo |
| Abbott Laboratories | $142.23 | 2020-2024 | Mitraclip |
| Lilly USA, LLC | $107.18 | 2021-2025 | Zepbound, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $86.68 | 2019-2023 | Farxiga |
| Akcea Therapeutics, INC. | $83.80 | 2019 | |
| Arbor Pharmaceuticals, INC. | $68.46 | 2019-2021 | |
| Esperion Therapeutics, INC. | $63.75 | 2021-2024 | Nexletol |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Leshner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.